Perrigo (PRGO) Reports Tentative FDA Approval For Generic Suprep; Confirms Patent Challenge For Generic Version Of Mirvaso Gel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel
August 23, 2016 9:10 AM EDTDUBLIN, Aug. 23, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016 were $178 million.
Perrigo today also announced that it was sued by Galderma Laboratories, L.P.... More
